Decheng Capital »

Scynexis shares owned by Decheng Capital

Quarter-by-quarter ownership of Scynexis (SCYX) shares owned by Decheng Capital from 13F filings

Historical chart of Decheng Capital investment in Scynexis

Tip: Access up to 7 years of quarterly data

All positions including Scynexis held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Scynexis by Decheng Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.2M 556k 2.23

More positions owned by Decheng Capital

Alpine Immune Sciences (ALPN)
Zentalis Pharmaceuticals (ZNTL)
Pacific Biosciences of California (PACB)
10x Genomics Cl A Com (TXG)
ImmunoGen
Arcus Biosciences Incorporated (RCUS)
Karuna Therapeutics Ord
Roivant Sciences Ltd Shs Isin #bmg762791017 (ROIV)
Illumina (ILMN)
Argenx SE SHS (ARGX)
Acelyrin (SLRN)
Krystal Biotech (KRYS)
Phathom Pharmaceuticals (PHAT)
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH)
Terns Pharmaceuticals (TERN)

View all positions for Decheng Capital

Top funds holding Scynexis

Federated Investors
Kingdon Capital Management
Vanguard Group
Avidity Partners Management
Decheng Capital
AMH Equity
D.A. Davidson & Co.
Bank of America Corporation
Man Group
Wealth Effects
Bank Of Montreal
Millennium Management
Chicago Partners Investment
O'shaughnessy Asset Management
GSA Capital Partners

View all funds holding Scynexis